Daniel Öhlund

Associate professor in oncology at Umeå Univerity. Pancreatic cancer researcher.

[Daniel Öhlund @DanielOhlund]

Happy to share that our project on the role of galectins in immune evasion has been awarded 6 MSEK in funding from the ErlingPersson Foundation. Grateful to the entire lab team and to the foundation for their support!

[Daniel Öhlund @DanielOhlund]

Back home from the Swedish Cancer Research Meeting in Malmö. Great meeting! Great contributions from our lab by Parniyan och Cedric!

[Daniel Öhlund @DanielOhlund]

Currently looking for a post-doc!
https://t.co/Fw9OjOGfqd

[Daniel Öhlund @DanielOhlund]

@Aiims1742 @nyulangone @Perlmutter_CC Congratulations!!

[Daniel Öhlund @DanielOhlund]

New paper published from our lab! Characterization of a new interferon-response CAFs with tumor-restraining properties.

https://t.co/nuAxjs8qw7

[nature @Nature]

Nature research paper: MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC

https://t.co/S4pDKykf1T

[Daniel Öhlund @DanielOhlund]

Currently looking for a post-doc!

https://t.co/0rhB40vbvt

[Chang-il Hwang @ChangilHwang]

🧵1/ Excited to share our latest review on how organoid technology is transforming pancreatic cancer research, published in Experimental & Molecular Medicine. Here's a breakdown of the key points. https://t.co/s6uuf2EqP7

[YOUPPIE Pancreas @YouppiePancreas]

🔥🔥 new day, 🆕 #pancreas2000 project 📣🤩

Pooled OR for pancreatic steatosis (PS) in patients with PDAC vs. controls was 3.23 (95% CI 1.86-5.60).

⬇️ ⬇️
https://t.co/2oUVoqNdfg

We need to prioritize a standardized approach to the diagnosis, follow-up, and treatment of PS.

[Giulia Biffi @BiffiGiulia]

Some highlights from the Botton-Champalimaud conference. Especially happy to see ⁦@vincorbo⁩ and ⁦@DanielOhlund⁩ continuing doing fab science. Nothing makes me happier than seeing good humans doing great.
💜💪🏻🌟

[Daniel Öhlund @DanielOhlund]

Our new review paper is out!

Overcoming therapy resistance in pancreatic cancer: New insights and future directions

https://t.co/zf7QfbMdAZ

[Daniel Öhlund @DanielOhlund]

The results from the NORPACT-1 trial are out! Conclusion: no survival benefit from neoadjuvant FOLFIRINOX in resectable pancreatic ductal adenocarcinoma compared with upfront surgery https://t.co/QZXrJWFz5E

[Umeå universitet @umeauniversitet]

Maréne Landström, Institutionen för medicinsk biovetenskap, har utsetts till Årets cancerforskare av Cancerfondens forskningsnämnd. Det är främst upptäckten av specialiserade antikroppar, som kan förhindra att prostatacancer sprider sig, som uppmärksammas. https://t.co/tBxR5Sb2xc

[Daniel Öhlund @DanielOhlund]

I’m looking for a postdoc to the lab!

https://t.co/Yi43AfdxLx

[Daniel Öhlund @DanielOhlund]

Congratulations to Joshua Cumming! PhD defence @UmeaUniversity yesterday. Great discussion with opponent @claus_jorgensen.

[Arndt Vogel @ArndtVogel]

🔥NORPACT-1: Short-course neoadjuvant FOLFIRINOX vs surgery + adj. therapy for #PDAC #ASCO23
🔎12 Nordic centers, phs-2, 140 pts
👉52% completed neoadj. CTx
🤨mOS: 25.1 mo vs 38.5 mo
✅manageable safety, but no benefit of neoadj. FOLFIRINOX
@myESMO @OncoAlert

[Malin Sund @MalinASund]

Jag är mycket hedrad över detta uppdrag 🙏🏻! Tack till @Cancerfonden och min företrädare professor Klas Kärre! ”Standing on the shoulders of giants”

[Daniel Öhlund @DanielOhlund]

Happy to join the #SwedishCancerResearchMeeting 2023!

[Cold Spring Harbor Laboratory @CSHL]

Today is #DNADay commemorating 70 years since “Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid” was published & 20 years since the completion of the Human Genome Project.

Let’s take a historical look back...🧬
https://t.co/wDDZ6JQuqm

[Christine Chio @Chiolaboratory]

Bench mate reunion at #GRCpancreas in Lucca Italy @DanielOhlund